

Identification of a Lead Compound for the Treatment of Skin Immune Diseases Using Next-Generation TPD Technology Targeting STAT3

Genexine, Inc.
Genexine

IMMUNOLOGY	Lead
Product Type	TPD
Indication	Atopic dermatitis (Skin immune disease)
Target	STAT3
MoA(Mechanism of Action)	Targeted STAT3 degradation via proteolysis
Competitiveness	<p>1. Superior Target Selectivity</p> <ul style="list-style-type: none"> Utilizes a high-affinity nanobody that binds specifically to STAT3, ensuring precise targeting Minimizes off-target effects by avoiding interaction with homologous proteins such as STAT1 or STAT5 <p>2. Potent Target Degradation via EPDeg™ Platform</p> <ul style="list-style-type: none"> Screened 23 different E3 ligases to identify the most efficient E3 for STAT3 degradation Achieves robust and sustained degradation of STAT3 protein <p>3. Enhanced Therapeutic Efficacy in Immune Modulation</p> <ul style="list-style-type: none"> Capable of suppressing not only Th2-mediated immune responses, but also broader immune activations such as Th17 and Th22 pathways
Development Stage	Lead
Route of Administration	Subcutaneous (SC) injection

Any unauthorized distribution or reproduction of this material is strictly prohibited.